Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jolan Walter

Pediatric Allergy/Immunology St Petersburg, FL Medical Doctor

NPI 1467649525 CMS profile 404749

601 5Th St S, Ach Outpatient Care Center, St Petersburg, FL 33701

Open in the dashboard

General payments

$232,220

235 records reported · program years 2019–2025

Research payments

$312,472

Paid to them · 43 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$841,377 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jolan Walter of St Petersburg, FL is reported in the CMS Open Payments database as having received $232,220 across 235 general payments and $312,472 in research payments paid to them. Separately, studies naming them as principal investigator received $841,377 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,270 48
2025 Research $41,866 10
2024 General $35,845 48
2024 Research $53,273 11
2023 General $64,971 56
2023 Research $44,264 7
2022 General $13,782 13
2022 Research $3,840 3
2021 General $22,518 16
2021 Research $169,229 12
2020 General $11,827 12
2019 General $20,007 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jolan Walter
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Jolan Walter were reported at $63,270. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Jolan Walter Pediatric Allergy/Immunology median Middle half National median
2019 $20,007 $325 $92–$1,399 $163
2020 $11,827 $144 $66–$2,490 $114
2021 $22,518 $357 $95–$2,633 $132
2022 $13,782 $385 $125–$2,259 $149
2023 $64,971 $470 $121–$2,946 $160
2024 $35,845 $317 $125–$2,583 $164
2025 $63,270 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pharming Healthcare, Inc. $140,696 121 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $29,511 25 payments
  3. Shire North American Group Inc $19,200 31 payments
  4. CSL Behring $9,737 8 payments
  5. Grifols Shared Services North America, Inc. $9,394 4 payments
  6. Chiesi USA, Inc. $8,320 4 payments
  7. Novartis Pharmaceuticals Corporation $7,407 7 payments
  8. ADMA BioManufacturing LLC $3,628 14 payments
  9. Regeneron Pharmaceuticals, Inc. $2,588 1 payment
  10. Octapharma USA, Inc. $406 4 payments
  11. Other $1,333 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $128,382 40 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,668 26 payments
  3. Travel and Lodging $17,014 66 payments
  4. Honoraria $7,699 6 payments
  5. Food and Beverage $5,433 96 payments
  6. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. JOENJA $95,202 73 payments
  2. CUVITRU $26,619 25 payments
  3. HYQVIA $16,737 24 payments
  4. Hizentra $7,852 4 payments
  5. Privigen $4,600 2 payments
  6. REVCOVI $4,224 3 payments
  7. Gamunex-C $4,035 2 payments
  8. RUCONEST $613 9 payments
  9. CUTAQUIG $406 4 payments
  10. Xembify $271 2 payments
  11. Other $1,021 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $299,412 38 payments
  2. Pharming Healthcare, Inc. $7,000 4 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $6,060 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

80

Median for Allergy/ Immunology: 449

Drug cost

$532,633

Median for Allergy/ Immunology: $169,700

Branded share of claims

100%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 36 $263,668
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 31 $154,028
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 13 $114,937

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$2,807

Medicare's payments for the services billed

Medicare patients

23

Average age 67

Services billed

30

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JOENJA
  • Pharming Healthcare, Inc. $18,140
$18,140 — —
REVCOVI
  • CHIESI USA, INC. $4,224
$4,224 — —
RUCONEST
  • Pharming Healthcare, Inc. $225
$225 — —
Xembify
  • Grifols Shared Services North America, Inc. $134
$134 — —
Hizentra
  • CSL Behring $22
$22 36 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record